114 related articles for article (PubMed ID: 24794908)
1. Gefitinib.
Rahman AF; Korashy HM; Kassem MG
Profiles Drug Subst Excip Relat Methodol; 2014; 39():239-64. PubMed ID: 24794908
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib.
Korashy HM; Rahman AF; Kassem MG
Profiles Drug Subst Excip Relat Methodol; 2014; 39():205-37. PubMed ID: 24794907
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Prescrire Int; 2004 Oct; 13(73):168-70. PubMed ID: 15499696
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib therapy for advanced non-small-cell lung cancer.
Liu CY; Seen S
Ann Pharmacother; 2003 Nov; 37(11):1644-53. PubMed ID: 14565788
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib, a novel, orally administered agent for the treatment of cancer.
Ranson M; Wardell S
J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
[TBL] [Abstract][Full Text] [Related]
8. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Li J; Karlsson MO; Brahmer J; Spitz A; Zhao M; Hidalgo M; Baker SD
J Natl Cancer Inst; 2006 Dec; 98(23):1714-23. PubMed ID: 17148773
[TBL] [Abstract][Full Text] [Related]
9. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
10. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
11. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
12. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Padda SK; Chhatwani L; Zhou L; Jacobs CD; Lopez-Anaya A; Wakelee HA
Anticancer Drugs; 2013 Aug; 24(7):731-5. PubMed ID: 23552470
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
Ando K; Ohmori T; Inoue F; Kadofuku T; Hosaka T; Ishida H; Shirai T; Okuda K; Hirose T; Horichi N; Nishio K; Saijo N; Adachi M; Kuroki T
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8872-9. PubMed ID: 16361577
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
18. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
19. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
Yan Y; Lu Y; Wang M; Vikis H; Yao R; Wang Y; Lubet RA; You M
Mol Cancer Res; 2006 Dec; 4(12):971-81. PubMed ID: 17189387
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]